GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Destiny Pharma PLC (LSE:DEST) » Definitions » Net Intangibles Purchase And Sale

Destiny Pharma (LSE:DEST) Net Intangibles Purchase And Sale : £-0.08 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Destiny Pharma Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Destiny Pharma's net Intangibles purchase and sale for the six months ended in Dec. 2023 was £0.00 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.08 Mil.

Destiny Pharma Net Intangibles Purchase And Sale Historical Data

The historical data trend for Destiny Pharma's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Destiny Pharma Net Intangibles Purchase And Sale Chart

Destiny Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -2.26 - - -0.08

Destiny Pharma Semi-Annual Data
Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.08 -

Destiny Pharma Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Destiny Pharma Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of Destiny Pharma's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

Destiny Pharma (LSE:DEST) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Destiny Pharma PLC (LSE:DEST) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
LSE:SBTX LSE:SAR LSE:TRX LSE:C4XD LSE:AREC LSE:ETX LSE:POLB LSE:4BB LSE:OPTI LSE:OBD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
D89:Germany
Address
Unit 36, Sussex Innovation Centre, Science Park Square, Falmer, Brighton, GBR, BN1 9SB
Website
https://www.destinypharma.com
Destiny Pharma PLC is a clinical-stage biotechnology company which is focused on the development of medicines for the treatment of infectious disease. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. It is involved in developing XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for prevention of post-surgical staphylococcal infection, XF Throat for prevention of staphylococcal hospital/ventilator-associated pneumonia infection.

Destiny Pharma (LSE:DEST) Headlines

No Headlines